We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Cystic Fibrosis Foundation (CFF) Biomarkers of Exacerbation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00788359
Recruitment Status : Completed
First Posted : November 10, 2008
Last Update Posted : December 2, 2014
Information provided by (Responsible Party):

November 6, 2008
November 10, 2008
December 2, 2014
December 2007
July 2012   (Final data collection date for primary outcome measure)
Change in concentration of individual protein biomarkers and various combinations of biomarkers in blood samples obtained pre and post IV antibiotic therapy [ Time Frame: up to 21 days ]
Same as current
Complete list of historical versions of study NCT00788359 on ClinicalTrials.gov Archive Site
  • Changes in pulmonary function (particularly FEV1) measured by spirometry pre and post IV antibiotic therapy [ Time Frame: Up to 21 days ]
  • Changes in bacterial densities (P. aeruginosa and other CF pathogens) in sputum samples obtained pre and post IV antibiotic therapy [ Time Frame: Up to 21 days ]
  • Changes in serum white blood cell and absolute neutrophil counts obtained pre and post IV antibiotic therapy [ Time Frame: Up to 21 days ]
Same as current
Not Provided
Not Provided
Cystic Fibrosis Foundation (CFF) Biomarkers of Exacerbation
Multi-center Trial to Validate Protein Biomarkers of a Pulmonary Exacerbation in Cystic Fibrosis
Clinical and translational research in cystic fibrosis (CF) is hampered by a lack of biomarkers that can be used to identify promising new therapies. There is an urgent need for development and validation of biomarkers that more quickly predict the usefulness of potential drugs in CF and might prognosticate clinical course. In particular, combinations of protein biomarkers that can be obtained non-invasively offer great promise. The goal of this project is to determine whether protein biomarkers in blood can demonstrate a beneficial effect of treatment over two weeks. We intend to initially target an acute pulmonary exacerbation in CF because we know that subjects being treated with intravenous antibiotics and enhanced mucus clearance display clinical improvements within two weeks. We propose to prospectively collect blood samples from a large cohort of well-characterized CF persons serially during inpatient admissions for a pulmonary exacerbation and longitudinally during annual visits. Through this proposal, we hope to identify a CF lung injury biomarker panel that increases in the setting of an acute pulmonary exacerbation and improves rapidly following intravenous antibiotic therapy. Additionally, we will begin to explore whether this CF lung injury biomarker panel might also prognosticate clinical course including decline in pulmonary function. Finally, this study will serve as an important source of blood samples that will be banked for future biomarker and therapeutic studies designed to benefit the entire CF community.
Not Provided
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Blood (plasma)
Non-Probability Sample
Individuals with CF greater than or equal to 10 years of age who are being started on intravenous (IV) antibiotics for a clinically diagnosed pulmonary exacerbation. Patients must demonstrate at least 3 of the 11 criteria for pulmonary exacerbation as defined by a Cystic Fibrosis Foundation (CFF) Consensus Conference. Treatment with a minimum of two IV antibiotics is required. We expect to enroll an approximately equal number of males and females. Most CF patients in our clinics are of white, non-Hispanic origin and we anticipate this ethnic mix to persist in this study. The majority of pediatric CF subjects will be admitted to the hospital for treatment purposes whereas many adults receive their IV antibiotics at home.
Cystic Fibrosis
Not Provided
Not Provided
Heltshe SL, Goss CH, Thompson V, Sagel SD, Sanders DB, Marshall BC, Flume PA. Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis. Thorax. 2016 Mar;71(3):223-9. doi: 10.1136/thoraxjnl-2014-206750. Epub 2015 Apr 24.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
July 2014
July 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis of CF as evidenced by a sweat chloride test >60mEq/L or by the presence of two known CF genetic mutations
  • Male or female greater than or equal to 10 years of age
  • Initiation of intravenous antibiotic therapy for a clinically diagnosed acute pulmonary exacerbation
  • Ability to perform reproducible pulmonary function tests
  • Willing to comply with the study procedures and willingness to provide written consent

Exclusion Criteria:

  • Presence of a condition or abnormality that, in the opinion of the Principal Investigator (PI), would compromise the safety of the patient or quality of the data
Sexes Eligible for Study: All
10 Years and older   (Child, Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
University of Colorado, Denver
University of Colorado, Denver
Cystic Fibrosis Foundation Therapeutics
Not Provided
University of Colorado, Denver
December 2014